title: Transport inhibition of digoxin using several common P-gp expressing cell lines is not necessarily reporting only on inhibitor binding to P-gp.
abstract: We have reported that the P-gp substrate digoxin required basolateral and apical uptake transport in excess of that allowed by digoxin passive permeability (as measured in the presence of GF120918) to achieve the observed efflux kinetics across MDCK-MDR1-NKI (The Netherlands Cancer Institute) confluent cell monolayers. That is, GF120918 inhibitable uptake transport was kinetically required. Therefore, IC50 measurements using digoxin as a probe substrate in this cell line could be due to inhibition of P-gp, of digoxin uptake transport, or both. This kinetic analysis is now extended to include three additional cell lines: MDCK-MDR1-NIH (National Institute of Health), Caco-2 and CPT-B2 (Caco-2 cells with BCRP knockdown). These cells similarly exhibit GF120918 inhibitable uptake transport of digoxin. We demonstrate that inhibition of digoxin transport across these cell lines by GF120918, cyclosporine, ketoconazole and verapamil is greater than can be explained by inhibition of P-gp alone. We examined three hypotheses for this non-P-gp inhibition. The inhibitors can: (1) bind to a basolateral digoxin uptake transporter, thereby inhibiting digoxin's cellular uptake; (2) partition into the basolateral membrane and directly reduce membrane permeability; (3) aggregate with digoxin in the donor chamber, thereby reducing the free concentration of digoxin, with concomitant reduction in digoxin uptake. Data and simulations show that hypothesis 1 was found to be uniformly acceptable. Hypothesis 2 was found to be uniformly unlikely. Hypothesis 3 was unlikely for GF120918 and cyclosporine, but further studies are needed to completely adjudicate whether hetero-dimerization contributes to the non-P-gp inhibition for ketoconazole and verapamil. We also find that P-gp substrates with relatively low passive permeability such as digoxin, loperamide and vinblastine kinetically require basolateral uptake transport over that allowed by +GF120918 passive permeability, while highly permeable P-gp substrates such as amprenavir, quinidine, ketoconazole and verapamil do not, regardless of whether they actually use the basolateral transporter.
authors: Department of Biology, Drexel University, Philadelphia, Pennsylvania, United States of America ; Preclinical Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America.
authors: Annie Albin
authors: AA
authors: Lumen
authors: Libin
authors: L
authors: Li
authors: Jiben
authors: J
authors: Li
authors: Zeba
authors: Z
authors: Ahmed
authors: Zhou
authors: Z
authors: Meng
authors: Albert
authors: A
authors: Owen
authors: Harma
authors: H
authors: Ellens
authors: Ismael J
authors: IJ
authors: Hidalgo
authors: Joe
authors: J
authors: Bentz
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics / Q000378:metabolism*; D000166:Acridines / Q000378:metabolism / Q000494:pharmacology; D000818:Animals; D018938:Caco-2 Cells; D002219:Carbamates / Q000378:metabolism / Q000494:pharmacology; D002463:Cell Membrane Permeability / Q000187:drug effects; D016572:Cyclosporine / Q000378:metabolism / Q000494:pharmacology; D004077:Digoxin / Q000037:antagonists & inhibitors* / Q000378:metabolism; D004285:Dogs; D005663:Furans; D015870:Gene Expression; D006801:Humans; D007654:Ketoconazole / Q000378:metabolism / Q000494:pharmacology; D007700:Kinetics; D008139:Loperamide / Q000378:metabolism / Q000494:pharmacology; D061985:Madin Darby Canine Kidney Cells; D011485:Protein Binding; D011802:Quinidine / Q000378:metabolism / Q000494:pharmacology; D013449:Sulfonamides / Q000378:metabolism / Q000494:pharmacology; D044005:Tetrahydroisoquinolines / Q000378:metabolism / Q000494:pharmacology; D014747:Vinblastine / Q000378:metabolism / Q000494:pharmacology
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000166:Acridines; D002219:Carbamates; D005663:Furans; D013449:Sulfonamides; D044005:Tetrahydroisoquinolines; C095108:amprenavir; D014747:Vinblastine; D008139:Loperamide; D004077:Digoxin; D016572:Cyclosporine; D011802:Quinidine; C083501:Elacridar; D007654:Ketoconazole
references: Drug Metab Dispos. 2010 Feb;38(2):260-9
references: 19889884
references: J Pharm Sci. 2011 Sep;100(9):4013-23
references: 21678427
references: Pharm Res. 2003 Aug;20(8):1192-9
references: 12948017
references: Drug Discov Today. 2013 Mar;18(5-6):218-39
references: 23207804
references: Biophys J. 2005 Jan;88(1):715-38
references: 15501934
references: ACS Chem Biol. 2012 Aug 17;7(8):1429-35
references: 22625864
references: Drug Metab Dispos. 2006 May;34(5):786-92
references: 16455806
references: J Med Chem. 2003 Oct 9;46(21):4477-86
references: 14521410
references: Biochemistry. 2006 Dec 26;45(51):15505-19
references: 17176072
references: J Pharmacol Exp Ther. 2001 Nov;299(2):620-8
references: 11602674
references: Biochemistry. 2005 Jan 18;44(2):643-55
references: 15641790
references: Nat Rev Drug Discov. 2010 Mar;9(3):215-36
references: 20190787
references: Drug Discov Today. 2006 Jul;11(13-14):607-15
references: 16793529
references: Drug Metab Dispos. 2011 Nov;39(11):2093-102
references: 21849517
references: Pharm Res. 2002 Jun;19(6):765-72
references: 12134945
references: Drug Metab Dispos. 2008 Feb;36(2):452-60
references: 17967933
references: J Biol Chem. 2000 Sep 29;275(39):30176-85
references: 10903312
references: Nat Rev Drug Discov. 2010 Aug;9(8):597-614
references: 20671764
references: Biochem Biophys Res Commun. 1993 Feb 15;190(3):760-6
references: 8439326
references: J Pharm Sci. 1998 Jun;87(6):757-62
references: 9607955
references: J Pharmacol Exp Ther. 2003 Aug;306(2):556-62
references: 12721332
references: Biophys J. 1997 Jul;73(1):267-76
references: 9199791
references: Drug Discov Today. 2012 Aug;17(15-16):905-12
references: 22507594
references: Mol Pharm. 2010 Apr 5;7(2):398-411
references: 20025245
references: J Membr Biol. 2005 Aug;206(3):173-85
references: 16456713
references: Drug Metab Dispos. 2011 Jan;39(1):47-53
references: 20926619
references: Nature. 2012 Oct 25;490(7421):566-9
references: 23000902
references: J Pharmacol Exp Ther. 2009 Sep;330(3):956-63
references: 19491323
references: Science. 2009 Mar 27;323(5922):1718-22
references: 19325113
references: J Pharmacol Exp Ther. 2002 Nov;303(2):574-80
references: 12388638
references: Pharm Res. 2001 Feb;18(2):171-6
references: 11405287
references: PLoS One. 2011;6(10):e25086
references: 22028772
references: Nat Rev Drug Discov. 2008 Mar;7(3):205-20
references: 18309312
references: Br J Cancer. 2000 Aug;83(3):366-74
references: 10917553